Vertex Pharmaceuticals Incorporated (VRTX34)
Sao Paulo Exchange · Brazil · prices in BRL · close of 23 Oct 2026
Key indicators
| Last close | BRL 82.80 |
|---|---|
| 52-week range | 65.18 – 89.01 |
| Return, 1 month / 3 months | −0.2% / +11.1% |
| Return, 1 year / 3 years | +16.2% / +44.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 53 |
| Volatility (1 year) | 33.7% |
| Worst drawdown (1 year) | -20.0% |
| Average daily value traded | 0.27M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Vertex Pharmaceuticals is a biopharmaceutical company based in Boston that discovers and develops medicines for serious diseases. Its main work centres on treatments for cystic fibrosis, a genetic condition affecting the lungs and other organs, and it also develops therapies for sickle cell disease, beta thalassemia, acute and neuropathic pain, and kidney disorders. Its customers are patients, physicians and healthcare systems, and it sells its products in markets around the world through its own commercial operations and partnerships.
Vertex Pharmaceuticals Incorporated is represented on the Sao Paulo Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code VRTX34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Vertex Pharmaceuticals Incorporated (VRTX34) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 82.80 on 23 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 123 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 16.2% and over the last three months it rose 11.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 77 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.1% | ||
| From 52-week high | -6.9% | ||
| Momentum | 74 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 11.1% | ||
| 6-month return | 21.3% | ||
| 12-month return, skipping the last month | 16.5% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 33.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.0% | ||
| Liquidity | 67 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.27M BRL | ||
| Zero-volume days | 18.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +4.0% |
|---|---|
| 1 month | −0.2% |
| 3 months | +11.1% |
| 6 months | +21.3% |
| 1 year | +16.2% |
| 3 years | +44.1% |
| 5 years | +154.9% |
Signals
| 50-day / 200-day average | 84.14 / 76.59 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.69 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.